Osta Biotechnologies Inc.
TSX VENTURE : OBI

Osta Biotechnologies Inc.

March 18, 2010 08:35 ET

Osta Biotechnologies Announces $504,000 Bought Deal Private Placement

MONTREAL, QUEBEC--(Marketwire - March 18, 2010) - Osta Biotechnologies Inc. (TSX VENTURE:OBI)

THE ISSUE OF THIS PRESS RELEASE IS LIMITED TO CANADA ONLY. THIS PRESS RELEASE SHOULD NOT BE ISSUED IN THE UNITED STATES THROUGH U.S. NEWS WIRE AGENCIES. 

Osta Biotechnologies Inc. (TSX VENTURE:OBI) is pleased to announce that it has entered into an agreement with Sherbrooke Street Capital Inc. for a "bough deal" private placement of 8,400,000 units at a price of $0.06 per unit, for gross proceeds to Osta of $504,000. Each unit will consist of one common share and one-half of a common share purchase warrant. Each whole warrant will entitle the holder to acquire one additional common share at a price of $0.10 for a period of two years from the closing of the private placement. The issue price of $0.06 was negotiated by Osta and Sherbrooke Street Capital in the context of the market.

Sherbrooke Street Capital intends to arrange for purchasers of the units in Canada on a prospectus-exempt basis. Closing of the private placement is expected to occur shortly.

In connection with the private placement, Sherbooke Street Capital will receive a fee equal to 7% of the gross proceeds of the offering. In addition, Osta will issue non-transferable broker warrants to Sherbooke Street Capital, entitling it to purchase a number of common shares of Osta equal to 7% of the number of units sold pursuant to the private placement. The broker warrants will be exercisable at a price of $0.10 per common share for a period of two years from the closing of the private placement.

The private placement is subject to regulatory approval, including that of the TSX Venture Exchange, and the signing of a definitive Underwriting Agreement between Osta and Sherbrooke Street Capital.

The securities issued in connection with the private placement will be subject to a four-month hold period under the policies of the TSX Venture Exchange and applicable securities legislation.

The net proceeds from the private placement will be used by Osta for research and development, as well as for working capital and general corporate purposes.

Osta would also like to confirm that, due to market conditions, it has decided not to proceed with the previously-announced $2.5 million private placement (see press release dated February 9, 2010).

About Osta Biotechnologies Inc.

Osta is a biopharmaceutical company listed on the TSX Venture Exchange currently focusing on developing therapeutics for Cancer and Alzheimer's disease.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Osta Biotechnologies Inc.
    Dr. Ajay Gupta
    Chairman & CEO
    514-626-9519